1. |
Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma [J]. Am J Surg, 1997; 173(4)∶358.
|
2. |
Lau WY, Leung TW, Ho SK, et al. Adjuvant intraarterial iodine131labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial [J]. Lancet, 1999; 353(9155)∶797.
|
3. |
de Baere T, Taourel P, Tubiana JM, et al. Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow [J]. Radiology, 1999; 212(3)∶665.
|
4. |
Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of I131labeled lipiodol. Part Ⅰ. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases [J]. Radiology, 1988; 168(2)∶541.
|
5. |
Ychou M, Pelegrin A, Faurous P, et al. PhaseI/II radioimmunotherapy study with iodine131labeled antiCEA monoclonal antibody F6 F(ab’)2 in patients with nonresectable liver metastases from colorectal cancer [J]. Int J Cancer, 1998; 75(4)∶615.
|
6. |
隋延仿,何风昌,陈志南.131碘肝癌单克隆抗体Fab片段偶合物体内放射免疫显像研究 [J]. 中华医学杂志, 1999; 78(7)∶537.
|
7. |
Novell R, Hilson A, Hobbs K. Ablation of recurrent primary liver cancer using 131Ilipiodol [J]. Postgrad Med J, 1991; 67(786) ∶393.
|
8. |
Ho S,Lau WY,Leung TW, et al. Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review [J]. Cancer, 1998; 83(9)∶1894.
|
9. |
Risse JH,Grunwald F,Strunk H, et al. I131lipiodol therapy in liver neoplasms [J]. Hybridoma, 1999; 18(1)∶83.
|
10. |
Brans B,De Winter F,Defreyne L, et al. The antitumoral activity of neoadjuvant intraarterial 131Ilipiodol treatment for hepatocellular carcinoma: a pilot study [J]. Cancer Biother Radiopharm, 2001; 16(4)∶333.
|
11. |
Partensky C, Sassolas G, Henry L, et al. Intraarterial iodine 131labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study [J]. Arch Surg, 2000; 135(11)∶1298.
|
12. |
Tan SB, Machin D, Cheung YB, et al. Following a trial that stopped early: what next for adjuvant hepatic intraarterial iodine131 lipiodol in resectable hepatocellular carcinoma? [J]. J Chin Oncol. 2002; 20(6)∶1709.
|
13. |
吴英德, 杨克政, 刘由庚, 等.131I抗AFP抗体导向治疗肝癌的临床观察 [J]. 肿瘤, 1994; 14(4)∶200.
|
14. |
Zeng ZC, Tang ZY, Liu KD, et al. Improved longterm survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131IantiHCC mAb. Phase I/II clinical trials [J]. J Cancer Res Clin Oncol, 1998; 124(5)∶275.
|
15. |
项明,朱上林,林言箴,等.131IHepama1单克隆抗体导向治疗肝癌的初步观察 [J]. 中国肿瘤临床, 1998; 25(4)∶289.
|
16. |
Abrams RA, Pajak TF, Haulk TL, et al. Survival results among patients with alphafetoproteinpositive,unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center [J]. Cancer J Sci Am, 1998; 4(3)∶178.
|